Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.

@article{Terrill2003SafetyDA,
  title={Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.},
  author={Kelly R Terrill and Richard S Lemons and Robert E Goldsby},
  journal={Journal of pediatric hematology/oncology},
  year={2003},
  volume={25 11},
  pages={864-7}
}
OBJECTIVES Recombinant tissue plasminogen activator, alteplase, began to be commonly used to restore the patency of occluded central venous catheters (CVCs) as urokinase production was halted in the late 1990s. However, alteplase often requires an extended dwell time to restore patency to occluded CVCs. In adults, reteplase, a newer thrombolytic agent, has been reported to restore patency to CVCs in 30 minutes. The authors prospectively evaluated the safety and efficacy of reteplase in… CONTINUE READING
7 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…